No-Reflow Phenomenon
14
2
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
43%
6 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
Alpha Lipoic Acid Effect on No-Reflow Phenomenon
A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
The EPIVER Randomized Controlled Trial
Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction
Adrenaline for the Treatment of No-Reflow in Normotensive Patients
the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)
NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
Intracoronary Tirofiban on No-Reflow Phenomena